TG Therapeutics, Inc. (TGTX)

TG Therapeutics, Inc. is trading at $54.37, up 0.06% on the session. The 50 day average sits at $53.65 and the 200 day at $42.01, which puts the stock in a uptrend. RSI is at 52.1, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $54.78 with resistance near $57.58, so that band frames the current range. Average daily movement is roughly $2.15, or about 4.0% of the share price, which is what any stop placement has to allow for. The overall health score of 69 out of 100 combines a trend score of 93, momentum of 44 and a risk score of 64.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.